Guardant Health, which makes non-invasive blood-based cancer diagnostics tests, announced terms for its IPO last Friday.
The Redwood City, CA-based company plans to raise $200 million by offering 12.5 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Guardant Health would command a fully diluted market value of $1.4 billion and an enterprise value of $944 million.
Guardant Health was founded in 2013 and booked $67 million in sales for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol GH. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. It is expected to price during the week of October 1, 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.